MX2008002369A - Moleculas cortas de acidos nucleicos de interferencia quimicamente modificadas que actuan de mediadoras de la interferencia del acido ribonucleico. - Google Patents
Moleculas cortas de acidos nucleicos de interferencia quimicamente modificadas que actuan de mediadoras de la interferencia del acido ribonucleico.Info
- Publication number
- MX2008002369A MX2008002369A MX2008002369A MX2008002369A MX2008002369A MX 2008002369 A MX2008002369 A MX 2008002369A MX 2008002369 A MX2008002369 A MX 2008002369A MX 2008002369 A MX2008002369 A MX 2008002369A MX 2008002369 A MX2008002369 A MX 2008002369A
- Authority
- MX
- Mexico
- Prior art keywords
- nucleotides
- coding strand
- nucleic acid
- sina
- strand
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 332
- 230000009368 gene silencing by RNA Effects 0.000 title claims abstract description 321
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 310
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 310
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 title claims abstract description 158
- 230000002452 interceptive effect Effects 0.000 title claims abstract description 39
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 269
- 230000014509 gene expression Effects 0.000 claims abstract description 165
- 238000000034 method Methods 0.000 claims abstract description 130
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 111
- 239000004055 small Interfering RNA Substances 0.000 claims abstract description 83
- 108020004459 Small interfering RNA Proteins 0.000 claims abstract description 80
- 239000000203 mixture Substances 0.000 claims abstract description 75
- 238000011282 treatment Methods 0.000 claims abstract description 74
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 68
- 230000000694 effects Effects 0.000 claims abstract description 63
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims abstract description 57
- 201000010099 disease Diseases 0.000 claims abstract description 56
- 239000003112 inhibitor Substances 0.000 claims abstract description 46
- 239000002679 microRNA Substances 0.000 claims abstract description 34
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 33
- 238000009472 formulation Methods 0.000 claims abstract description 31
- 238000012423 maintenance Methods 0.000 claims abstract description 23
- 238000011161 development Methods 0.000 claims abstract description 22
- 230000006870 function Effects 0.000 claims abstract description 21
- 150000001875 compounds Chemical class 0.000 claims abstract description 20
- 150000002632 lipids Chemical class 0.000 claims abstract description 13
- 238000013456 study Methods 0.000 claims abstract description 9
- 108091027967 Small hairpin RNA Proteins 0.000 claims abstract description 8
- 108091070501 miRNA Proteins 0.000 claims abstract description 8
- 239000002105 nanoparticle Substances 0.000 claims abstract description 6
- 230000033077 cellular process Effects 0.000 claims abstract description 5
- 238000003745 diagnosis Methods 0.000 claims abstract description 4
- 230000009711 regulatory function Effects 0.000 claims abstract description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 736
- 239000002773 nucleotide Substances 0.000 claims description 712
- 108091033380 Coding strand Proteins 0.000 claims description 377
- 239000002213 purine nucleotide Substances 0.000 claims description 160
- 230000000295 complement effect Effects 0.000 claims description 158
- 239000002719 pyrimidine nucleotide Substances 0.000 claims description 124
- 150000003230 pyrimidines Chemical class 0.000 claims description 119
- 108091028664 Ribonucleotide Proteins 0.000 claims description 67
- 239000002336 ribonucleotide Substances 0.000 claims description 67
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 54
- 239000005547 deoxyribonucleotide Substances 0.000 claims description 46
- 241000700721 Hepatitis B virus Species 0.000 claims description 35
- 108700011259 MicroRNAs Proteins 0.000 claims description 28
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 26
- 125000005642 phosphothioate group Chemical group 0.000 claims description 24
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 claims description 17
- 230000002401 inhibitory effect Effects 0.000 claims description 15
- 239000003085 diluting agent Substances 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims 1
- -1 (e.g. Substances 0.000 abstract description 17
- 230000037361 pathway Effects 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 description 182
- 108091030071 RNAI Proteins 0.000 description 162
- 150000003212 purines Chemical class 0.000 description 137
- 210000001519 tissue Anatomy 0.000 description 129
- 108091092724 Noncoding DNA Proteins 0.000 description 126
- 108091026890 Coding region Proteins 0.000 description 96
- 239000002585 base Substances 0.000 description 92
- 230000004048 modification Effects 0.000 description 86
- 238000012986 modification Methods 0.000 description 86
- 238000007385 chemical modification Methods 0.000 description 66
- 238000003776 cleavage reaction Methods 0.000 description 59
- 230000007017 scission Effects 0.000 description 59
- 102000040430 polynucleotide Human genes 0.000 description 57
- 108091033319 polynucleotide Proteins 0.000 description 57
- 239000002157 polynucleotide Substances 0.000 description 57
- 208000035475 disorder Diseases 0.000 description 55
- 108091034117 Oligonucleotide Proteins 0.000 description 50
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 48
- 239000012634 fragment Substances 0.000 description 48
- 125000005647 linker group Chemical group 0.000 description 35
- 230000004044 response Effects 0.000 description 31
- 235000000346 sugar Nutrition 0.000 description 31
- 230000002194 synthesizing effect Effects 0.000 description 29
- 230000003308 immunostimulating effect Effects 0.000 description 28
- 230000001225 therapeutic effect Effects 0.000 description 27
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 26
- 229960003205 adefovir dipivoxil Drugs 0.000 description 26
- 108091028043 Nucleic acid sequence Proteins 0.000 description 25
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 25
- 229960001627 lamivudine Drugs 0.000 description 25
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 24
- 235000018102 proteins Nutrition 0.000 description 24
- 238000000338 in vitro Methods 0.000 description 23
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 22
- 230000002265 prevention Effects 0.000 description 22
- 230000018109 developmental process Effects 0.000 description 20
- 239000002777 nucleoside Substances 0.000 description 20
- 230000015572 biosynthetic process Effects 0.000 description 19
- 150000003833 nucleoside derivatives Chemical class 0.000 description 19
- 229920001223 polyethylene glycol Polymers 0.000 description 19
- 239000002202 Polyethylene glycol Substances 0.000 description 18
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 18
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 18
- 230000001976 improved effect Effects 0.000 description 17
- 238000001990 intravenous administration Methods 0.000 description 17
- 238000007920 subcutaneous administration Methods 0.000 description 17
- 238000007910 systemic administration Methods 0.000 description 17
- 208000015181 infectious disease Diseases 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 16
- 230000000670 limiting effect Effects 0.000 description 16
- 238000003786 synthesis reaction Methods 0.000 description 16
- 108700026244 Open Reading Frames Proteins 0.000 description 15
- 230000001413 cellular effect Effects 0.000 description 15
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 15
- 102000002689 Toll-like receptor Human genes 0.000 description 14
- 108020000411 Toll-like receptor Proteins 0.000 description 14
- 239000003446 ligand Substances 0.000 description 14
- 230000001404 mediated effect Effects 0.000 description 14
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 14
- 238000003556 assay Methods 0.000 description 13
- 108091023037 Aptamer Proteins 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 12
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 12
- 235000012000 cholesterol Nutrition 0.000 description 12
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 12
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 12
- 231100000583 toxicological profile Toxicity 0.000 description 12
- 230000030279 gene silencing Effects 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 230000001052 transient effect Effects 0.000 description 11
- 230000006806 disease prevention Effects 0.000 description 10
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 150000008163 sugars Chemical class 0.000 description 10
- 208000035657 Abasia Diseases 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 9
- 230000002238 attenuated effect Effects 0.000 description 9
- 230000010468 interferon response Effects 0.000 description 9
- 108091008104 nucleic acid aptamers Proteins 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 125000000547 substituted alkyl group Chemical group 0.000 description 9
- 229910052717 sulfur Inorganic materials 0.000 description 9
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000005451 thionucleotide Substances 0.000 description 8
- 238000013519 translation Methods 0.000 description 8
- UIYWFOZZIZEEKJ-XVFCMESISA-N 1-[(2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound F[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 UIYWFOZZIZEEKJ-XVFCMESISA-N 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- 102000014150 Interferons Human genes 0.000 description 7
- 108010050904 Interferons Proteins 0.000 description 7
- 102000004889 Interleukin-6 Human genes 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 101710163270 Nuclease Proteins 0.000 description 7
- 244000097202 Rathbunia alamosensis Species 0.000 description 7
- 235000009776 Rathbunia alamosensis Nutrition 0.000 description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
- 125000002877 alkyl aryl group Chemical group 0.000 description 7
- 125000003710 aryl alkyl group Chemical group 0.000 description 7
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 7
- 229940100601 interleukin-6 Drugs 0.000 description 7
- 125000003835 nucleoside group Chemical group 0.000 description 7
- 229920000768 polyamine Polymers 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 101150054147 sina gene Proteins 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 229940113082 thymine Drugs 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 7
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 6
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 6
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 229920002873 Polyethylenimine Polymers 0.000 description 6
- WVOXLKUUVCCCSU-ZPFDUUQYSA-N Pro-Glu-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WVOXLKUUVCCCSU-ZPFDUUQYSA-N 0.000 description 6
- 102000006382 Ribonucleases Human genes 0.000 description 6
- 108010083644 Ribonucleases Proteins 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 6
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 229940014144 folate Drugs 0.000 description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 6
- 235000019152 folic acid Nutrition 0.000 description 6
- 239000011724 folic acid Substances 0.000 description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000026447 protein localization Effects 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 229940063673 spermidine Drugs 0.000 description 6
- 229940063675 spermine Drugs 0.000 description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 6
- 229940035893 uracil Drugs 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- NVZFZMCNALTPBY-XVFCMESISA-N 4-amino-1-[(2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](F)[C@H](O)[C@@H](CO)O1 NVZFZMCNALTPBY-XVFCMESISA-N 0.000 description 5
- 206010007559 Cardiac failure congestive Diseases 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 5
- 102100023387 Endoribonuclease Dicer Human genes 0.000 description 5
- 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 description 5
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 125000004103 aminoalkyl group Chemical group 0.000 description 5
- 125000005122 aminoalkylamino group Chemical group 0.000 description 5
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 208000019423 liver disease Diseases 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 230000000926 neurological effect Effects 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 108091027963 non-coding RNA Proteins 0.000 description 5
- 102000042567 non-coding RNA Human genes 0.000 description 5
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 150000003431 steroids Chemical class 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- SXUXMRMBWZCMEN-UHFFFAOYSA-N 2'-O-methyl uridine Natural products COC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-UHFFFAOYSA-N 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 4
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 4
- 229910004679 ONO2 Inorganic materials 0.000 description 4
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 125000002015 acyclic group Chemical group 0.000 description 4
- 150000003838 adenosines Chemical class 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 239000005289 controlled pore glass Substances 0.000 description 4
- 125000001651 cyanato group Chemical group [*]OC#N 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000012226 gene silencing method Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 229940047124 interferons Drugs 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 208000017169 kidney disease Diseases 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 208000030159 metabolic disease Diseases 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 208000023504 respiratory system disease Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- JXNPEDYJTDQORS-HZJYTTRNSA-N (9Z,12Z)-octadecadien-1-ol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCO JXNPEDYJTDQORS-HZJYTTRNSA-N 0.000 description 3
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 3
- PGYFLJKHWJVRMC-ZXRZDOCRSA-N 2-[4-[[(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]butoxy]-n,n-dimethyl-3-[(9z,12z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OCCCCOC(CN(C)C)COCCCCCCCC\C=C/C\C=C/CCCCC)C1 PGYFLJKHWJVRMC-ZXRZDOCRSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 3
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 3
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 3
- 229930010555 Inosine Natural products 0.000 description 3
- 102000006992 Interferon-alpha Human genes 0.000 description 3
- 108010047761 Interferon-alpha Proteins 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 3
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 3
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 3
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 210000003027 ear inner Anatomy 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 208000030533 eye disease Diseases 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 229960003786 inosine Drugs 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- JXNPEDYJTDQORS-UHFFFAOYSA-N linoleyl alcohol Natural products CCCCCC=CCC=CCCCCCCCCO JXNPEDYJTDQORS-UHFFFAOYSA-N 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 description 3
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- ZGYYPTJWJBEXBC-QYYRPYCUSA-N (2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol Chemical class C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1F ZGYYPTJWJBEXBC-QYYRPYCUSA-N 0.000 description 2
- RFCQJGFZUQFYRF-UHFFFAOYSA-N 2'-O-Methylcytidine Natural products COC1C(O)C(CO)OC1N1C(=O)N=C(N)C=C1 RFCQJGFZUQFYRF-UHFFFAOYSA-N 0.000 description 2
- SXUXMRMBWZCMEN-ZOQUXTDFSA-N 2'-O-methyluridine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-ZOQUXTDFSA-N 0.000 description 2
- ZDTFMPXQUSBYRL-UUOKFMHZSA-N 2-Aminoadenosine Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ZDTFMPXQUSBYRL-UUOKFMHZSA-N 0.000 description 2
- UXUZARPLRQRNNX-DXTOWSMRSA-N 2-amino-9-[(2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1F UXUZARPLRQRNNX-DXTOWSMRSA-N 0.000 description 2
- PJWBTAIPBFWVHX-FJGDRVTGSA-N 4-amino-1-[(2r,3s,4r,5r)-3-fluoro-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical class O=C1N=C(N)C=CN1[C@H]1[C@](F)(O)[C@H](O)[C@@H](CO)O1 PJWBTAIPBFWVHX-FJGDRVTGSA-N 0.000 description 2
- NVZFZMCNALTPBY-PXBUCIJWSA-N 4-amino-1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](F)[C@H](O)[C@@H](CO)O1 NVZFZMCNALTPBY-PXBUCIJWSA-N 0.000 description 2
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 2
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 2
- KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 2
- OZFPSOBLQZPIAV-UHFFFAOYSA-N 5-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=C2NC=CC2=C1 OZFPSOBLQZPIAV-UHFFFAOYSA-N 0.000 description 2
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 241000244206 Nematoda Species 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000011374 additional therapy Methods 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 208000027115 auditory system disease Diseases 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- 230000004700 cellular uptake Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 108091036078 conserved sequence Proteins 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000016097 disease of metabolism Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 102000054767 gene variant Human genes 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 208000016354 hearing loss disease Diseases 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 2
- 238000002663 nebulization Methods 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000007126 proinflammatory cytokine response Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000002718 pyrimidine nucleoside Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 101150003485 unc-22 gene Proteins 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- 229940045145 uridine Drugs 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical class C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
- LKUDPHPHKOZXCD-UHFFFAOYSA-N 1,3,5-trimethoxybenzene Chemical compound COC1=CC(OC)=CC(OC)=C1 LKUDPHPHKOZXCD-UHFFFAOYSA-N 0.000 description 1
- SGKGZYGMLGVQHP-ZOQUXTDFSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-methylpyrimidine-2,4-dione Chemical compound CC1=CC(=O)NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 SGKGZYGMLGVQHP-ZOQUXTDFSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- 102100027962 2-5A-dependent ribonuclease Human genes 0.000 description 1
- 108010000834 2-5A-dependent ribonuclease Proteins 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- AEXIQPQOFKQACC-UHFFFAOYSA-N 2-ethoxypyrimidine Chemical compound CCOC1=NC=CC=N1 AEXIQPQOFKQACC-UHFFFAOYSA-N 0.000 description 1
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- VPLZGVOSFFCKFC-UHFFFAOYSA-N 3-methyluracil Chemical compound CN1C(=O)C=CNC1=O VPLZGVOSFFCKFC-UHFFFAOYSA-N 0.000 description 1
- LOJNBPNACKZWAI-UHFFFAOYSA-N 3-nitro-1h-pyrrole Chemical compound [O-][N+](=O)C=1C=CNC=1 LOJNBPNACKZWAI-UHFFFAOYSA-N 0.000 description 1
- JYVNKMPUWUYANG-UHFFFAOYSA-N 4-(difluoromethoxy)-2-ethoxypyrimidine Chemical compound CCOC1=NC=CC(OC(F)F)=N1 JYVNKMPUWUYANG-UHFFFAOYSA-N 0.000 description 1
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 1
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 1
- AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 1
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 1
- BHEHGFHLZIDTEH-UHFFFAOYSA-N 8-(difluoromethoxy)-2-ethoxy-7h-purine Chemical compound CCOC1=NC=C2NC(OC(F)F)=NC2=N1 BHEHGFHLZIDTEH-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 125000000824 D-ribofuranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@]1([H])O[H] 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000016621 Hearing disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000034991 Hiatal Hernia Diseases 0.000 description 1
- 206010020028 Hiatus hernia Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000780643 Homo sapiens Protein argonaute-2 Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000425347 Phyla <beetle> Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 102100034207 Protein argonaute-2 Human genes 0.000 description 1
- 101710092489 Protein kinase 2 Proteins 0.000 description 1
- 241000269435 Rana <genus> Species 0.000 description 1
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 description 1
- 102100026839 Sterol regulatory element-binding protein 1 Human genes 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- SIIZPVYVXNXXQG-KGXOGWRBSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(3s,4r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Polymers C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)OC2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OCC([C@@H](O)[C@H]1O)OC1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-KGXOGWRBSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000002032 cellular defenses Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000019113 chromatin silencing Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- ZPTBLXKRQACLCR-XVFCMESISA-N dihydrouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)CC1 ZPTBLXKRQACLCR-XVFCMESISA-N 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 102000010982 eIF-2 Kinase Human genes 0.000 description 1
- 108010037623 eIF-2 Kinase Proteins 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004373 eye development Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical group CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical compound CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001526 topogenic effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/205,646 US20080161256A1 (en) | 2001-05-18 | 2005-08-17 | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| US11/234,730 US20070270579A1 (en) | 2001-05-18 | 2005-09-23 | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| US73702405P | 2005-11-15 | 2005-11-15 | |
| US11/299,254 US20060217331A1 (en) | 2001-05-18 | 2005-12-08 | Chemically modified double stranded nucleic acid molecules that mediate RNA interference |
| PCT/US2006/032168 WO2007022369A2 (en) | 2005-08-17 | 2006-08-17 | Chemically modified short interfering nucleic acid molecules that mediate rna interference |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2008002369A true MX2008002369A (es) | 2008-03-18 |
Family
ID=40328218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2008002369A MX2008002369A (es) | 2005-08-17 | 2006-08-17 | Moleculas cortas de acidos nucleicos de interferencia quimicamente modificadas que actuan de mediadoras de la interferencia del acido ribonucleico. |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JP2009504190A (enrdf_load_stackoverflow) |
| BR (1) | BRPI0614407A2 (enrdf_load_stackoverflow) |
| IL (1) | IL189540A0 (enrdf_load_stackoverflow) |
| MX (1) | MX2008002369A (enrdf_load_stackoverflow) |
| NO (1) | NO20081376L (enrdf_load_stackoverflow) |
| NZ (1) | NZ565712A (enrdf_load_stackoverflow) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009086174A1 (en) | 2007-12-21 | 2009-07-09 | Srs Labs, Inc. | System for adjusting perceived loudness of audio signals |
| JP5730508B2 (ja) * | 2009-07-10 | 2015-06-10 | アンジェスＭｇ株式会社 | 炎症性腸疾患の治療又は予防剤 |
| US8538042B2 (en) | 2009-08-11 | 2013-09-17 | Dts Llc | System for increasing perceived loudness of speakers |
| US9312829B2 (en) | 2012-04-12 | 2016-04-12 | Dts Llc | System for adjusting loudness of audio signals in real time |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050233996A1 (en) * | 2002-02-20 | 2005-10-20 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA) |
| EP1432724A4 (en) * | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | INTERFERENCE MEDIATION INHIBITION OF GENE RNA FROM MAP KINASE |
-
2006
- 2006-08-17 MX MX2008002369A patent/MX2008002369A/es active IP Right Grant
- 2006-08-17 NZ NZ565712A patent/NZ565712A/en not_active IP Right Cessation
- 2006-08-17 BR BRPI0614407-1A patent/BRPI0614407A2/pt not_active IP Right Cessation
- 2006-08-17 JP JP2008527139A patent/JP2009504190A/ja active Pending
-
2008
- 2008-02-14 IL IL189540A patent/IL189540A0/en unknown
- 2008-03-14 NO NO20081376A patent/NO20081376L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0614407A2 (pt) | 2009-08-18 |
| NO20081376L (no) | 2008-05-16 |
| NZ565712A (en) | 2011-09-30 |
| IL189540A0 (en) | 2008-08-07 |
| JP2009504190A (ja) | 2009-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1931781B1 (en) | Chemically modified short interfering nucleic acid molecules that mediate rna interference | |
| EP1627061B1 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | |
| US20080249294A1 (en) | RNA Interference Mediated Inhibition of Gene Expression Using Short Interfering Nucleic Acid (siNA) | |
| US20090176725A1 (en) | Chemically modified short interfering nucleic acid molecules that mediate rna interference | |
| US20070185049A1 (en) | RNA interference mediated inhibition of histone deacetylase (HDAC) gene expression using short interfering nucleic acid (siNA) | |
| US20070160980A1 (en) | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) | |
| US20050227935A1 (en) | RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA) | |
| US20060276422A1 (en) | RNA interference mediated inhibition of B7-H1 gene expression using short interfering nucleic acid (siNA) | |
| US20060217331A1 (en) | Chemically modified double stranded nucleic acid molecules that mediate RNA interference | |
| US9994853B2 (en) | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference | |
| JP2008506351A (ja) | 短鎖干渉核酸（ｓｉＮＡ）を用いる、ＲＮＡ干渉を介した遺伝子発現の阻害 | |
| WO2007067981A2 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | |
| US20100145038A1 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | |
| EP1817415A2 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF INTERLEUKIN AND INTERLEUKIN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | |
| US7943757B2 (en) | RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA) | |
| US7923549B2 (en) | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA) | |
| US20050187174A1 (en) | RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA) | |
| CN101426912A (zh) | 介导rna干扰的化学修饰短干扰核酸分子 | |
| RU2418068C2 (ru) | Молекулы химически модифицированной короткой интерферирующей нуклеиновой кислоты, которые опосредуют интерференцию рнк | |
| US20070270579A1 (en) | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) | |
| WO2008030239A1 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF HISTONE DEACETYLASE (HDAC) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | |
| US8008473B2 (en) | RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA) | |
| US20080161256A1 (en) | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) | |
| MX2008002369A (es) | Moleculas cortas de acidos nucleicos de interferencia quimicamente modificadas que actuan de mediadoras de la interferencia del acido ribonucleico. | |
| US20090137510A1 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/ REL-A GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |